Nexalin Technology, Inc.
No SEC Form 4 filings for $NXL in the last 30 days.
See all $NXL insider activity →Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 nexalintec_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Note Purchase Agreement This Note Purchase Agreement (this “ Agreement ”), dated as of August 21, 2026, is entered into by and between Nexalin Technology, Inc., a Delaware corporation (“ Company ”), and Streeterville Capit
Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 6 nexalintec_ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH
Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001527352 0001527352 2026-08-11 2026-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
Over the past 7 days, alphai's AI scored 2 news stories mentioning NXL (Nexalin Technology, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent NXL coverage spans financial news, corporate actions and technology.
Minor capital raise adds $1 M net cash; limited immediate price impact.
Potential dilution and cash infusion of up to $15M; short‑term price pressure likely.
Shareholder votes confirm which capital-structure actions were approved (equity plan, preferred stock authorization) and which were rejected (reverse stock splits, officer exculpation).
The 8-K discloses a new lease amendment with rent levels, a five-month base-rent abatement, and an extension option, which can affect near-term operating costs and cash burn.
Positive clinical readout for Nexalin’s non-invasive DIFS protocol supports commercialization confidence and can re-rate risk for the stock.
alphai scores every news story that mentions NXL with an AI model for sentiment and relevance, and aggregates insider trades from Nexalin Technology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 nexalintec_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Note Purchase Agreement This Note Purchase Agreement (this “ Agreement ”), dated as of August 21, 2026, is entered into by and between Nexalin Technology, Inc., a Delaware corporation (“ Company ”), and Streeterville Capit
1 min readNexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 6 nexalintec_ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE SUCH TERMS ARE BOTH NOT MATERIAL AND ARE THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH
1 min readNexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001527352 0001527352 2026-08-11 2026-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
2 min readNexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001527352 0001527352 2026-07-28 2026-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readNexalin Technology (NXL) reported positive eight-week clinical trial results for its non-invasive DIFS neurostimulation in adults with generalized anxiety disorder and comorbid insomnia. Conducted at the University of São Paulo’s Institute of Psychiatry, the study used a 15 mA, 77.5 Hz protocol across 20 40-minute sessions. Nexalin said the end-of-treatment anxiety response rate was 77.8% (HAM-A drop by Session 5 and maintained at follow-up), with no serious adverse events.
4 min readNexalin Technology, Inc. praised recent bipartisan Congressional initiatives that expand federal focus on deep brain neurostimulation research within the VA and NIH. The company actively participated in shaping legislation to increase veterans' access to emerging treatments, especially those for traumatic brain injury, PTSD, stroke recovery, and Alzheimer's disease. Nexalin's DIFS™ technology is recognized as a sophisticated non-invasive neurostimulation method and is currently being evaluated in research with UC San Diego and the San Diego VA community.
3 min readNexalin Technology (NXL) lauded recent Congressional actions that increase federal backing for deep brain neurostimulation research, stating its DIFS™ technology aligns with VA and NIH priorities. The company highlighted two appropriations reports signed into law supporting neuromodulation research and an ongoing study with UC San Diego/San Diego VA using DIFS™. While H.R. 7091 is still under committee review, Nexalin sees these legislative moves as a significant step toward recognizing neurostimulation as a high-potential therapeutic approach for conditions like TBI, PTSD, and Alzheimer's.
3 min readPeer-reviewed case report published in The American Journal on Addictions highlights significant clinical improvement and sustained abstinence following Nexalin's non-invasive therapy Peer-reviewed case report published in The American Journal on Addictions highlights significant clinical ...
3 min readAppointment Follows Israeli Ministry of Health Approval for Nexalin's Gen-2 SYNC Device Appointment Follows Israeli Ministry of Health Approval for Nexalin's Gen-2 SYNC Device ...
3 min readHOUSTON, TX, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Nexalin Technology, Inc. ( Nasdaq: NXL ) ( the "Company" or "Nexalin" ) , the leader in Deep Intracranial Frequency Stimulation ( DIFS™ ) of the brain, today announced that its Gen-2 Console ( "SYNC" ) , 15 milliamp ( mA ) neurostimulation device ...
4 min read
